Latest Strategic Outlook News

Tambourah Metals reports significant gold assay results extending mineralisation at Tambourah King and confirms high-grade antimony, silver, and copper at Speewah North, alongside corporate updates including a new CEO appointment and capital raising.

Mont Royal Resources reported a net cash outflow in Q2 2025 driven by one-off merger expenses, while outlining plans for a capital raising to support ongoing operations.

Zelira Therapeutics reports promising diabetic neuropathy study results with ZLT-L-007 surpassing Lyrica, while converting $3.25 million in notes to equity to bolster HOPE® 1 clinical development.

Astron Corporation Limited’s securityholders have overwhelmingly approved a scheme to shift the company’s domicile from Hong Kong to Australia, setting the stage for a significant corporate restructuring.

Aeris Environmental reported a robust 62% revenue increase in the June 2025 quarter, driven by new international contracts and expanding adoption of its Syncromesh IoT platform.

Orion Minerals reported significant cash outflows in its June 2025 quarter, with liquidity stretched and financing facilities nearly maxed out. The company is pursuing a $5.8 million capital raising to support ongoing operations following recent feasibility study completions.

Cynata Therapeutics is advancing three pivotal clinical trials targeting acute Graft versus Host Disease, osteoarthritis, and kidney transplantation, with major results expected through early 2026. The company maintains a solid cash position supporting its clinical pipeline and strategic growth.

NGX Limited progresses its Malingunde graphite project with technical studies and stakeholder engagement, while uranium exploration permits advance in Namibia. The company stands to benefit from new US anti-dumping tariffs on Chinese graphite imports.

Vitrafy Life Sciences reported robust progress in Q4 FY2025, advancing its cryopreservation technology and commercial partnerships while preparing for a pivotal product launch in FY2026.

Donaco International’s Q4 FY2025 results reveal a revenue dip driven by geopolitical tensions at its Star Vegas casino, while its Vietnam hotel posts gains. Meanwhile, the company’s proposed acquisition by On Nut Road Limited moves closer to shareholder approval.

Opthea has discontinued its sozinibercept program after Phase 3 trial failures, leading to drastic staff cuts and a sharp decline in cash reserves amid ongoing funding negotiations.

Legacy Iron Ore Limited reported solid progress in its June 2025 quarter, with ongoing gold production at South Laverton and key development milestones at the Mount Bevan magnetite project.